BioPharma Dive December 11, 2024
The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million from a syndicate of nearly 20 investors.
Epigenetic editing startup Chroma Medicine is merging with Nvelop Therapeutics in a deal that will also bring in $75 million in funding to develop in vivo genetic medicines, the two companies announced Wednesday.
The combination will bring together technologies the companies describe as complementary: epigenetic editors from Chroma and non-viral particles from Nvelop capable of delivering those editors into the body. The new firm, dubbed nChroma Bio, will be led by Nvelop’s CEO Jeff Walsh.
Conversations about merging Chroma and Nvelop began in earnest a few months ago, at a dinner in late September between Walsh...
Today's Sponsors
Today's Sponsor